The Motley Fool

Why Cronos Group Inc. (TSX:CRON) Could Be a Better Buy Than Canopy Growth Corp (TSX:WEED)

There is lots of competition in the cannabis industry already, and any edge that a company can achieve could easily set it apart from the rest, especially when it comes to producing a superior product and in helping to make the business more profitable.

On Tuesday, Cronos Group (TSX:CRON)(NASDAQ:CRON) announced a deal with Ginkgo Bioworks Inc. where the two companies would partner together to develop cannabis in a lab rather than having to grow and extract chemicals from a plant. Ginkgo has a decade of experience working with microorganisms and designing them for various types of products, including pharmaceuticals.

Why does this matter?

Ginkgo’s technology can help to make the extraction process a lot more efficient, and while the cannabinoid molecules would be the same as those extracted from a plant, more could be obtained through this process. In the news release announcing this deal, it also notes that “the use of Ginkgo’s platform is expected to unlock access to potentially medically important and valuable cannabinoids that are present only in low quantities in the plant.”

By being able to extract more medical benefits from cannabis, that could put Cronos ahead of its peers in the medical marijuana market. The opportunity could create a lot more potential products that could treat patients, and that would lead to even greater demand for cannabis.

One product that could be attractive to non-medicinal users would be tetrahydrocannabivarin (THCV), which, unlike tetrahydrocannabinol (THC), can help give people a high without making them hungry, which is one of the known side effects of pot. THCV is difficult to extract from a plant and would be in much lower quantities than would be available under Ginkgo’s process. For the recreational market, THCV would certainly have a lot of appeal to users and could help Cronos differentiate its products from its peers.

The other big benefit from this process is that not only would Cronos be able to extract more molecules from this process, but it would also be more cost efficient to do so. For one, the company wouldn’t have to purchase all the space and farms that its peers do, and that will not only keep its need for capital down, but operating expenses will also be much lower than that of a typical cannabis company.

By focusing on efficiency, Cronos can utilize the technological benefits of producing cannabis in a lab and keep its costs lower and more predictable. One of the advantages of this is that its financials will be more useful. For example, in Canopy Growth’s (TSX:WEED)(NYSE:CGC) latest quarterly report, the company got a big boost from gains related to its plants. That volatility makes it difficult for investors to be able to predict how a company like Canopy Growth will be able to perform in the future. Cronos will be able to avoid that with lab-created pot, which should make its margins more consistent.

Bottom line

While Canopy Growth may be the dominant player in the industry today, with this deal Cronos could prove to be more efficient and unlock a lot more growth potential. Being able to produce a quality product while making a profit is something that’s still a challenge in the industry, and Cronos may have found a way to do it.

Our #1 Stock to Buy in 2018 (and Beyond!)

When you buy heavily cyclical stocks at low prices… and then hold the shares until the cycle reaches its peak… you can make a very healthy profit.

Every investor knows that. But many struggle to identify the best opportunities.

Except The Motley Fool may have a plan to solve that problem! Our in-house analyst team has poured thousands of hours into their proprietary research – and this is the result.

Our top advisor Iain Butler has just identified his #1 stock to buy in 2018 (and beyond).

The last time this stock went from the low point of its cycle to the peak… shares shot from $12 to $40 inside of 4 years. That’s an 300%-plus return. And if you missed out on that ride, today might just be your second chance.

Click here to claim Iain’s new report, absolutely FREE!

Fool contributor David Jagielski has no position in any of the stocks mentioned.

I consent to receiving information from The Motley Fool via email, direct mail, and occasional special offer phone calls. I understand I can unsubscribe from these updates at any time. Please read the Privacy Statement and Terms of Service for more information.